Using advanced computer models to improve bladder cancer treatment schedules
Multiscale Computational Models Guided By Emerging Cellular Dynamics Quantification For Predicting Optimum Immune Checkpoint And Targeted Therapy Schedules
This study is looking to create a new computer program that helps doctors find the best treatment plans for people with advanced bladder cancer by using both math and real patient data, aiming to improve the effectiveness of current therapies for those who haven't had much success with standard chemotherapy.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Michigan at Ann Arbor NIH-funded |
| Lab location | 1 site (Ann Arbor, United States) |
| Project ID | NIH-10834157 on NIH RePORTER |
What this research studies
This research aims to develop a sophisticated 3D computational framework that combines mathematical modeling with experimental data to optimize treatment schedules for bladder cancer. By focusing on the immune checkpoint pathway and small molecule inhibitors, the project seeks to enhance the effectiveness of existing therapies. Patients with advanced bladder cancer, who often have poor outcomes with traditional chemotherapy, may benefit from this innovative approach that integrates computational predictions with clinical strategies.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with advanced bladder cancer who have not responded well to standard chemotherapy.
Not a fit: Patients with early-stage bladder cancer or those who have not been diagnosed with bladder cancer may not receive any benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment schedules for bladder cancer, improving patient outcomes.
How similar studies have performed: Other research has shown promise in using computational models to optimize cancer treatments, indicating that this approach could be effective.
Where this research is happening
Ann Arbor, United States
- University of Michigan at Ann Arbor — Ann Arbor, United States (Active)
Researchers
- Principal investigator: Jackson, Trachette — University of Michigan at Ann Arbor
- Study coordinator: Jackson, Trachette
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.